EpiVax Overview
- Year Founded
-
1998
- Status
-
Private
- Employees
-
47
- Latest Deal Type
-
Buyout/LBO
- Financing Rounds
-
18
- Investments
-
1
EpiVax General Information
Description
Developer of a biotechnology platform designed to create and implement computational immunology tools to benefit the biotechnology industry. The company's platform utilizes scientific and technological assets related to epitope discovery, de-immunization, and vaccine design through a mix of collaborative and internal programs, enabling physicians to have access to immunotherapeutics that offer protection with few side effects.
Contact Information
Website
www.epivax.comCorporate Office
- 188 Valley Street
- Suite 424
- Providence, RI 02909
- United States
Corporate Office
- 188 Valley Street
- Suite 424
- Providence, RI 02909
- United States
EpiVax Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
EpiVax Comparisons
Industry
Financing
Details
EpiVax Competitors (1)
One of EpiVax’s competitors is Lonza Biologics, a Corporation company based in Morristown, NJ.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Lonza Biologics | Corporation | Morristown, NJ |
EpiVax Patents
EpiVax Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026101714-A1 | Universal t cell targeted influenza vaccine construct | Pending | 05-Nov-2024 | ||
| WO-2025024775-A1 | Modified interferon-beta-1 having reduced immunogenicity | Inactive | 26-Jul-2023 | ||
| WO-2023004307-A1 | T cell epitopes and related compositions useful in the prevention and treatment of respiratory syncytial virus infection | Inactive | 19-Jul-2021 | ||
| WO-2022251216-A1 | T cell epitopes and related compositions useful in the prevention, diagnosis, and treatment of beta-coronaviruses | Inactive | 24-May-2021 | ||
| WO-2022174151-A1 | Prophylactic broad spectrum vaccine for sars-cov-2 | Inactive | 12-Feb-2021 | C07K14/005 |
EpiVax Signals
EpiVax Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
EpiVax Investments (1)
EpiVax’s most recent deal was a Seed Round with EpiVax Therapeutics for . The deal was made on 25-Sep-2017.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| EpiVax Therapeutics | 25-Sep-2017 | Seed Round | Drug Discovery |
EpiVax Exits (1)
EpiVax’s most recent exit was on 25-Sep-2017 from EpiVax Therapeutics. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| EpiVax Therapeutics | 25-Sep-2017 | Completed |
|
EpiVax FAQs
-
When was EpiVax founded?
EpiVax was founded in 1998.
-
Where is EpiVax headquartered?
EpiVax is headquartered in Providence, RI.
-
What is the size of EpiVax?
EpiVax has 47 total employees.
-
What industry is EpiVax in?
EpiVax’s primary industry is Drug Discovery.
-
Is EpiVax a private or public company?
EpiVax is a Private company.
-
What is EpiVax’s current revenue?
The current revenue for EpiVax is .
-
Who are EpiVax’s investors?
Escalate Capital Partners and SV Health Investors have invested in EpiVax.
-
Who are EpiVax’s competitors?
Lonza Biologics is a competitor of EpiVax.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process